Janne Lehtiö
Professor
Karolinska Institutet, Sweden
InFLAMES Visiting Professor
Professor Janne Lehtiö and the LehtiöLab focuses on proteomics and proteogenomics to gain new knowledge on molecular phenotype of cancer and use that information to improve personalized medicine.
Research description
Our major research interest is to improve proteomics and proteogenomics to obtain new molecular information on cancer and use this information to improve and personalize future cancer treatments. Proteomics research aims to study thousands of proteins simultaneously in a sample to obtain a molecular picture of the ongoing biology. In cancer, this proteome wide analysis provides data on how certain genotype and environmental factors combined can drive tumour growth. We thrive to use this knowledge to improve cancer therapy by discovering new biomarkers and therapy targets. Lehtiö’s group has published number of novel methods for proteome analysis and omics data-analysis. The main focus on our clinical proteomics and system biology research is on lung and breast cancer fields as well as on a newly started program on childhood cancers and leukemia. We work also for clinical implementation of omics data via our Molecular Tumor board portal.
Research description
Our major research interest is to improve proteomics and proteogenomics to obtain new molecular information on cancer and use this information to improve and personalize future cancer treatments. Proteomics research aims to study thousands of proteins simultaneously in a sample to obtain a molecular picture of the ongoing biology. In cancer, this proteome wide analysis provides data on how certain genotype and environmental factors combined can drive tumour growth. We thrive to use this knowledge to improve cancer therapy by discovering new biomarkers and therapy targets. Lehtiö’s group has published number of novel methods for proteome analysis and omics data-analysis. The main focus on our clinical proteomics and system biology research is on lung and breast cancer fields as well as on a newly started program on childhood cancers and leukemia. We work also for clinical implementation of omics data via our Molecular Tumor board portal.
